<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580654</url>
  </required_header>
  <id_info>
    <org_study_id>CSL312_1003</org_study_id>
    <nct_id>NCT04580654</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults</brief_title>
  <official_title>A 2-Part, Phase 1, Single Center, Open-label, Single Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Subcutaneous and Intravenous CSL312 in Healthy Adult Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a 2- part, phase 1, open-label, single center, single ascending dose study to&#xD;
      investigate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of&#xD;
      subcutaneous (SC) and intravenous (IV) administration of CSL312 in healthy adult Japanese and&#xD;
      Caucasian subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2020</start_date>
  <completion_date type="Actual">May 7, 2021</completion_date>
  <primary_completion_date type="Actual">May 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of CSL312 after subcutaneous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from time 0 extrapolated to infinity (AUC0-inf) of CSL312 after subcutaneous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax) of CSL312 after subcutaneous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 to the last measurable concentration (AUC0-last) of CSL312 after subcutaneous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of CSL312 after subcutaneous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F) of CSL312 after subcutaneous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of CSL312 after subcutaneous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CSL312 after intravenous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CSL312 after intravenous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-last of CSL312 after intravenous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf of CSL312 after intravenous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of CSL312 after intravenous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of CSL312 after intravenous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) of CSL312 after intravenous dosing</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean FXIIa-mediated kallikrein activity</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing adverse events (AEs)</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects experiencing AEs</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing serious adverse events (SAEs)</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects experiencing SAEs</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing adverse events of special interest (AESIs)</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects experiencing AESIs</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing Anti-CSL312 antibodies</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects experiencing Anti-CSL312 antibodies</measure>
    <time_frame>Up to 85 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with injection / infusion site reaction by severity</measure>
    <time_frame>Up to 48 hours after start of infusion or injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with injection / infusion site reaction by severity</measure>
    <time_frame>Up to 48 hours after start of infusion or injection</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>CSL312 (Cohort 1a, low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Factor XIIa antagonist monoclonal antibody administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL312 (Cohort 1b, low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Factor XIIa antagonist monoclonal antibody administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL312 (Cohort 2, high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Factor XIIa antagonist monoclonal antibody administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL312 (Cohort 3, low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Factor XIIa antagonist monoclonal antibody administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL312 (Cohort 4, high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Factor XIIa antagonist monoclonal antibody administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL312</intervention_name>
    <description>Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa</description>
    <arm_group_label>CSL312 (Cohort 1a, low dose)</arm_group_label>
    <arm_group_label>CSL312 (Cohort 1b, low dose)</arm_group_label>
    <arm_group_label>CSL312 (Cohort 2, high dose)</arm_group_label>
    <arm_group_label>CSL312 (Cohort 3, low dose)</arm_group_label>
    <arm_group_label>CSL312 (Cohort 4, high dose)</arm_group_label>
    <other_name>Factor XIIa antagonist monoclonal antibody</other_name>
    <other_name>garadacimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Caucasian and Japanese male or female subjects 18 to 55 years old (inclusive)&#xD;
             that meet the following criteria at Screening:&#xD;
&#xD;
               -  Japanese subjects defined as being born in Japan, having not lived outside of&#xD;
                  Japan for more than 10 years, and having both parents and four grandparents who&#xD;
                  are of Japanese ancestry.&#xD;
&#xD;
               -  Caucasian subjects, defined as having both parents and four grandparents&#xD;
                  descended from and of the peoples of Europe, the Middle East, or North Africa,&#xD;
                  who are body weight-matched (± 15%) 1:1 with Japanese subjects.&#xD;
&#xD;
          -  Body weight in the range of ≥ 50 kg and ≤ 100 kg&#xD;
&#xD;
          -  Body mass index of ≥ 18 kg/m2 and ≤ 30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive serology test for human immunodeficiency virus (HIV)-1 / 2 antibody,&#xD;
             hepatitis B virus (HBV) surface antigen (HBsAg) or hepatitis C virus (HCV) antibody.&#xD;
&#xD;
          -  Received any live viral or bacterial vaccinations within 8 weeks of Screening or is&#xD;
             expected to receive any live virus or bacterial vaccinations during the study.&#xD;
&#xD;
          -  Evidence of current active infection.&#xD;
&#xD;
          -  Known malignancy or a history of malignancy in the past 5 years .&#xD;
&#xD;
          -  Blood pressure or pulse rate measurements outside the normal range for the subject's&#xD;
             age.&#xD;
&#xD;
          -  Female subject of childbearing potential or fertile male subject either not using or&#xD;
             not willing to use an acceptable method of contraception&#xD;
&#xD;
          -  Pregnant, breastfeeding, or not willing to cease breastfeeding.&#xD;
&#xD;
          -  Donation or loss of more than 500 mL of blood within 3 months, or donated plasma&#xD;
             within 7 days&#xD;
&#xD;
          -  History of clinically significant arterial or venous thrombosis, bleeding disorder, or&#xD;
             any abnormal coagulation test result&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.&#xD;
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.&#xD;
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.</ipd_time_frame>
    <ipd_access_criteria>Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.&#xD;
An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.&#xD;
The requesting party must execute an appropriate data sharing agreement before IPD will be made available.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

